Interleukin-6 inhibits receptor activator of nuclear factor kappaB ligand-induced osteoclastogenesis by diverting cells into the macrophage lineage: key role of Serine727 phosphorylation of signal transducer and activator of transcription 3.
暂无分享,去创建一个
[1] Bodo Grimbacher,et al. STAT3 mutations in the hyper-IgE syndrome. , 2007, The New England journal of medicine.
[2] H. Takada,et al. Dominant-negative mutations in the DNA-binding domain of STAT3 cause hyper-IgE syndrome , 2007, Nature.
[3] G. Stark,et al. Unphosphorylated STAT3 accumulates in response to IL-6 and activates transcription by binding to NFkappaB. , 2007, Genes & development.
[4] Soo Young Lee,et al. Protein Inhibitor of Activated STAT 3 Modulates Osteoclastogenesis by Down-Regulation of NFATc1 and Osteoclast-Associated Receptor1 , 2007, The Journal of Immunology.
[5] Soo Young Lee,et al. MafB negatively regulates RANKL-mediated osteoclast differentiation. , 2007, Blood.
[6] M. Padrines,et al. Key roles of the OPG–RANK–RANKL system in bone oncology , 2007, Expert review of anticancer therapy.
[7] A. Teti,et al. Impaired skeletal development in interleukin-6-transgenic mice: a model for the impact of chronic inflammation on the growing skeletal system. , 2006, Arthritis and rheumatism.
[8] N. Reich,et al. Tracking STAT nuclear traffic , 2006, Nature Reviews Immunology.
[9] N. Ip,et al. STAT3 as a Downstream Mediator of Trk Signaling and Functions* , 2006, Journal of Biological Chemistry.
[10] G. Roodman. Regulation of Osteoclast Differentiation , 2006, Annals of the New York Academy of Sciences.
[11] Xin-Yuan Fu,et al. Osteoporosis with increased osteoclastogenesis in hematopoietic cell-specific STAT3-deficient mice. , 2005, Biochemical and biophysical research communications.
[12] Mone Zaidi,et al. Osteoclast signalling pathways. , 2005, Biochemical and biophysical research communications.
[13] S. Théoleyre,et al. The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling. , 2004, Cytokine & growth factor reviews.
[14] S. Théoleyre,et al. Relevance of an in vitro osteoclastogenesis system to study receptor activator of NF-kB ligand and osteoprotegerin biological activities. , 2004, Experimental cell research.
[15] T. Martin,et al. Glycoprotein 130 regulates bone turnover and bone size by distinct downstream signaling pathways. , 2004, The Journal of clinical investigation.
[16] Kwan Tat Steeve,et al. IL-6, RANKL, TNF-alpha/IL-1: interrelations in bone resorption pathophysiology. , 2004 .
[17] P. Heinrich,et al. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. , 2003, The Biochemical journal.
[18] J. Karras,et al. Serine phosphorylation of STAT3 is essential for Mcl-1 expression and macrophage survival. , 2003, Blood.
[19] David L. Lacey,et al. Osteoclast differentiation and activation , 2003, Nature.
[20] L. Mosekilde,et al. Age-related changes in cortical bone content of insulin-like growth factor binding protein (IGFBP)-3, IGFBP-5, osteoprotegerin, and calcium in postmenopausal osteoporosis: a cross-sectional study. , 2003, The Journal of clinical endocrinology and metabolism.
[21] N. Athanasou,et al. Interleukin-6 and interleukin-11 support human osteoclast formation by a RANKL-independent mechanism. , 2002, Bone.
[22] Noriaki Yoshida,et al. U0126 and PD98059, Specific Inhibitors of MEK, Accelerate Differentiation of RAW264.7 Cells into Osteoclast-like Cells* , 2002, The Journal of Biological Chemistry.
[23] U. Lerner,et al. IL-6, Leukemia Inhibitory Factor, and Oncostatin M Stimulate Bone Resorption and Regulate the Expression of Receptor Activator of NF-κB Ligand, Osteoprotegerin, and Receptor Activator of NF-κB in Mouse Calvariae1 , 2002, The Journal of Immunology.
[24] F. Speleman,et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes , 2002, Genome Biology.
[25] D. Heymann,et al. Osteoclastic acidification pathways during bone resorption. , 2002, Bone.
[26] D. Chauhan,et al. Biologic sequelae of interleukin-6 induced PI3-K/Akt signaling in multiple myeloma , 2001, Oncogene.
[27] G. Roodman. Studies in Paget's disease and their relevance to oncology. , 2001, Seminars in oncology.
[28] M. Tsujimoto,et al. Involvement of p38 Mitogen-activated Protein Kinase Signaling Pathway in Osteoclastogenesis Mediated by Receptor Activator of NF-κB Ligand (RANKL)* , 2000, The Journal of Biological Chemistry.
[29] F. Hoek,et al. Elevation of systemic markers related to cardiovascular diseases in the peripheral blood of periodontitis patients. , 2000, Journal of periodontology.
[30] D. Heymann,et al. gp130 Cytokine family and bone cells. , 2000, Cytokine.
[31] T. Chambers. Regulation of the differentiation and function of osteoclasts , 2000, The Journal of pathology.
[32] H. Gascan,et al. Functional Interaction of STAT3 Transcription Factor with the Cell Cycle Inhibitor p21 WAF1/CIP1/SDI1 * , 2000, The Journal of Biological Chemistry.
[33] Xinmin Cao,et al. Serine Phosphorylation and Negative Regulation of Stat3 by JNK* , 1999, The Journal of Biological Chemistry.
[34] T. Boone,et al. Novel neurotrophin-1/B cell-stimulating factor-3: a cytokine of the IL-6 family. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[35] C. O’Brien,et al. STAT3 Activation in Stromal/Osteoblastic Cells Is Required for Induction of the Receptor Activator of NF-κB Ligand and Stimulation of Osteoclastogenesis by gp130-utilizing Cytokines or Interleukin-1 but Not 1,25-Dihydroxyvitamin D3 or Parathyroid Hormone* , 1999, The Journal of Biological Chemistry.
[36] N. Udagawa,et al. A new member of tumor necrosis factor ligand family, ODF/OPGL/TRANCE/RANKL, regulates osteoclast differentiation and function. , 1999, Biochemical and biophysical research communications.
[37] S. Holland,et al. Hyper-IgE syndrome with recurrent infections--an autosomal dominant multisystem disorder. , 1999, The New England journal of medicine.
[38] S. Morony,et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis , 1999, Nature.
[39] Xinmin Cao,et al. Repression of Stat3 activity by activation of mitogen-activated protein kinase (MAPK) , 1998, Oncogene.
[40] Li Sun,et al. Mode of Action of Interleukin-6 on Mature Osteoclasts. Novel Interactions with Extracellular Ca2+ Sensing in the Regulation of Osteoclastic Bone Resorption , 1998, The Journal of cell biology.
[41] P. Heinrich,et al. Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway. , 1998, The Biochemical journal.
[42] I. Morita,et al. Expression of IL-6 receptor and GP130 in mouse bone marrow cells during osteoclast differentiation. , 1998, Bone.
[43] D. Lacey,et al. Osteoprotegerin Ligand Is a Cytokine that Regulates Osteoclast Differentiation and Activation , 1998, Cell.
[44] K Yano,et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[45] G. Daculsi,et al. Cytokines, growth factors and osteoclasts. , 1998, Cytokine.
[46] J. Blenis,et al. STAT3 serine phosphorylation by ERK-dependent and -independent pathways negatively modulates its tyrosine phosphorylation , 1997, Molecular and cellular biology.
[47] Brian R. Wong,et al. TRANCE Is a Novel Ligand of the Tumor Necrosis Factor Receptor Family That Activates c-Jun N-terminal Kinase in T Cells* , 1997, The Journal of Biological Chemistry.
[48] J. Darnell. STATs and gene regulation. , 1997, Science.
[49] A. Grey,et al. Circulating levels of interleukin-6 and tumor necrosis factor-alpha are elevated in primary hyperparathyroidism and correlate with markers of bone resorption--a clinical research center study. , 1996, The Journal of clinical endocrinology and metabolism.
[50] J. Pessin,et al. Insulin Stimulates the Serine Phosphorylation of the Signal Transducer and Activator of Transcription (STAT3) Isoform (*) , 1996, The Journal of Biological Chemistry.
[51] M. Davie,et al. Osteoclasts are not the major source of interleukin-6 in mouse parietal bones. , 1996, Bone.
[52] N. Udagawa,et al. Interleukin‐6 and soluble interleukin‐6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast‐like cell formation , 1996, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[53] F. Takahashi,et al. Bone marrow neutrophilia and suppressed bone turnover in human interleukin-6 transgenic mice. A cellular relationship among hematopoietic cells, osteoblasts, and osteoclasts mediated by stromal cells in bone marrow. , 1995, The American journal of pathology.
[54] S. Akira,et al. Interleukin-6 family of cytokines and gp130. , 1995, Blood.
[55] J. Darnell,et al. Maximal activation of transcription by statl and stat3 requires both tyrosine and serine phosphorylation , 1995, Cell.
[56] A. Flanagan,et al. The effect of interleukin‐6 and soluble interleukin‐6 receptor protein on the bone resorptive activity of human osteoclasts generated in vitro , 1995, The Journal of pathology.
[57] T. J. Hall,et al. Wortmannin, a potent inhibitor of phosphatidylinositol 3-kinase, inhibits osteoclastic bone resorption in vitro , 1995, Calcified Tissue International.
[58] Sakae Tanaka,et al. Wortmannin, a specific inhibitor of phosphatidylinositol‐3 kinase, blocks osteoclastic bone resorption , 1995, FEBS letters.
[59] R. Jilka,et al. Bone marrow, cytokines, and bone remodeling. Emerging insights into the pathophysiology of osteoporosis. , 1995, The New England journal of medicine.
[60] N. Udagawa,et al. Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[61] G. Passeri,et al. 17 beta-estradiol inhibits interleukin-6 production by bone marrow-derived stromal cells and osteoblasts in vitro: a potential mechanism for the antiosteoporotic effect of estrogens. , 1992, The Journal of clinical investigation.
[62] M. Jourdan,et al. Murine anti-interleukin-6 monoclonal antibody therapy for a patient with plasma cell leukemia. , 1991, Blood.
[63] M. Jourdan,et al. Interleukin-6 is the central tumor growth factor in vitro and in vivo in multiple myeloma. , 1990, European cytokine network.
[64] B. Epker,et al. Correlation of Bone Resorption and Formation with the Physical Behavior of Loaded Bone , 1965, Journal of dental research.
[65] J. Tuukkanen,et al. Gap-junctional regulation of osteoclast function. , 2003, Critical reviews in eukaryotic gene expression.
[66] Z. Lee,et al. The phosphatidylinositol 3-kinase, p38, and extracellular signal-regulated kinase pathways are involved in osteoclast differentiation. , 2002, Bone.
[67] T. Hanyu,et al. Mineral density and histomorphometric assessment of bone changes in the proximal tibia early after induction of type II collagen-induced arthritis in growing and mature rats , 2001, Journal of Bone and Mineral Metabolism.
[68] J. Schuringa. Molecular analysis and biological implications of STAT3 signal transduction , 2001 .